1. Home
  2. ZYME vs CNXC Comparison

ZYME vs CNXC Comparison

Compare ZYME & CNXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$26.11

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo Concentrix Corporation

CNXC

Concentrix Corporation

HOLD

Current Price

$24.03

Market Cap

1.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZYME
CNXC
Founded
2003
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.7B
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
ZYME
CNXC
Price
$26.11
$24.03
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
5
Target Price
$38.90
$54.80
AVG Volume (30 Days)
625.3K
2.1M
Earning Date
05-07-2026
03-24-2026
Dividend Yield
N/A
5.79%
EPS Growth
33.33
N/A
EPS
N/A
1.20
Revenue
$105,965,000.00
$9,825,771,000.00
Revenue This Year
$183.10
$5.29
Revenue Next Year
N/A
$2.49
P/E Ratio
N/A
$19.67
Revenue Growth
38.87
2.15
52 Week Low
$11.86
$19.12
52 Week High
$29.75
$62.14

Technical Indicators

Market Signals
Indicator
ZYME
CNXC
Relative Strength Index (RSI) 63.53 43.45
Support Level $22.44 $22.05
Resistance Level $26.75 $34.64
Average True Range (ATR) 1.11 1.92
MACD 0.40 -0.18
Stochastic Oscillator 84.13 54.11

Price Performance

Historical Comparison
ZYME
CNXC

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

About CNXC Concentrix Corporation

Concentrix Corp is a technology and services company. It designs, implements, and manages end-to-end solutions, including customer experience process optimization, technology development and design engineering, front- and back-office automation, analytics, and business transformation services. The company serves clients across multiple industry verticals, helping them manage customer engagement and operational processes throughout the customer lifecycle. The company operates in a single operating segment. It generates revenue through the provision of technology and services under contractual arrangements. Geographically, the company generates the maximum revenue from the Philippines and the rest from India, the United States, Great Britain, Germany, Canada and Other countries.

Share on Social Networks: